Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.

Slides:

Advertisements

Similar presentations

Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.

Advertisements

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

Measuring the latent HIV Reservoir

Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

2014 “Towards an HIV Cure” symposium Melbourne Following in vitro culture with myeloid dendritic cells, negative regulators of T cell activation are expressed.

Unique integration patterns in an in vitro model of HIV-1 latency. Suha M. Saleh, Dimitrios Vatakis, Andrew Harman, Anthony Cunningham, Paul U. Cameron,

Contribution of the immune system to HIV persistence Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

S Collins, I-Base: Introduction to cure researchUK-CAB January 2013 HIV cure research: pieces in the puzzle Simon Collins HIV i-Base.

Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.

Track A Report Guido Poli Vita-Salute San Raffaele University & Scientific Institute, Milano, Italy XVIII International AIDS Conference, Vienna, 2010.

Main questions on HIV persistence and on obstacles to HIV eradication Jean-Pierre Routy M.D. McGill University Montreal Toward an HIV cure: Insight into.

Natural and induced control of HIV infection: differences and similarities VISCONTI Study Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales.

Instructions To use this template: –for each slide write the correct answer on the orange bar first –choose which option (A,B,C or D) and make sure you.

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

HIV Latency: Molecular Mechanisms Eric Verdin, MD Associate Director and Senior Investigator.

Myeloid dendritic cells and HIV latency in resting T-cells Nitasha A Kumar, Vanessa A Evans, Suha Saleh, Candida de Fonseca Pereira, Paula Ellenberg, Paul.

EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.

Measuring the latent HIV Reservoir

Strategies for Targeting and Eradicating the HIV Reservoir

2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.

HIV Science Update from Rome to Addis : Basic Science Coumba Toure Kane Dakar University Senegal.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.

Future directions in HIV basic science research The hunt for a cure.

Slide 1 of 10 From DC Douek, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation, HIV Persistence,

Latent infection and cellular reservoirs

Estrogen blocks HIV re-emergence from latency and points to gender- specific differences in HIV reservoirs Jonathan Karn International AIDS Society Hammer.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

HIV Organ Policy Equity (HOPE) Act Research Criteria: follow-up discussion Advisory Committee on Organ Transplantation April 13, 2015.

HIV Cellular Pathogenesis III

Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.

Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.

Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,

Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,

HAART Therapy Christine Ashton Christy Naylor Katherine Tompkins.

Has someone been cured of HIV?. Some background on HIV O Causes AIDS O Mutates rapidly O Infects T cells of the immune system O Lysogenic (can hide inside.

Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.

HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.

Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.

Myeloid dendritic cells induce HIV-1 latency in non- proliferating CD4 + T cells IAS WORKSHOP, 16 & 17 JULY 2010.

HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.

Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.

Medical Microbiology Chapter 49 Mechanisms of Viral Pathogenesis.

HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.

Mechanisms of HIV Latency

ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.

HBV (chronic) HIV ~400 million chronically infected

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,

Immune reconstitution Anjie Zhen, PhD

HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.

Background  HIV-1 infection persists in reservoirs and leads to progressive depletion of CD4+ T-cells even in subjects with slow disease progression 

Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:

The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.

Catherine K. Koofhethile 21st IAS July,2016 Durban, SA

HIV Cure: Current Status and Future Perspectives

Katsin MA, Vitebsk State Medical University (Belarus)

HEATHER Feedback Meeting

Human Health and Disease

Didier Trono, Flavia Marzetta Cell Host & Microbe

HIV-1 Latency by Transition

Y. Sun, J. Li, J. Ma, C. Wang, F. Bai, K. Zhao, Z. Yu, W. Kang,

The block-and-lock approach

Residual HIV replication + virus/cell latency + viral sanctuaries

Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy Steven G. Deeks, Bruce D. Walker

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection Lin Shen, MD, Robert F. Siliciano,

Keep control: Elite and post-treatment controllers

Presentation transcript:

Title Box

“Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART fail to cure and what are the mechanisms for HIV persistence during HAART? -How can we cure HIV?

“The journey of a thousand miles begins with one step” Lao Tzu

Title Box “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART fail to cure and what are the mechanisms for HIV persistence during HAART? -How can we cure HIV?

Title Box

Chronic Immune Activation

Title Box -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART fail to cure and what are the mechanisms for HIV persistence during HAART? -How can we cure HIV?

Title Box ?

A Roadmap to an HIV Cure

Title Box

What Have We Learned from Δ32/Δ32 stem cell transplantation? -HIV infection is critically dependent on CCR5 -HIV persistence is critically dependent on CCR5 -The role of tissues not derived from bone marrow in persistence and infection is in question But… n=1!

What Have We Learned from the Elite Controllers? -Defined by the ability to spontaneously suppress plasma viremia -Occurs in less than 1% of HIV-infected individuals -Elevated CD4 cell counts, stable CD4 trajectories, and more favorable clinical outcomes -Overrepresentation of protective HLA alleles -Other mechanisms under active study -Immune Control of HIV infection is possible!

Title Box -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART fail to cure and what are the mechanisms for HIV persistence during HAART? -How can we cure HIV?

Title Box

HIV Latency in CD4 + T cells - CD4 + T cell latency is established at the transcriptional level predominantly in central memory T cells -CD4 + T cell latency is rare (1/ resting CD4 T cells) -Sequence of latent proviruses does not evolve, suggesting no or low ongoing viral replication. -Patients successfully treated with HAART for longer than 10 years exhibit no appreciable decrease in the size of the latent reservoir.

Title Box Disulfiram ? ? ? ?

Title Box

HIV Latency at the Molecular Level

Title Box

HIV Latency at the Molecular Level

Title Box

-Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART fail to cure and what are the mechanisms for HIV persistence during HAART? -How can we cure HIV?

Title Box A Roadmap to an HIV Cure

Title Box

Jon Cohen, Science 2011;332:784

IAS International Working Group

Carine Van Lint Stephane Emiliiani Melanie Ott Albert Jordan Dwayne Bisgrove Tokameh Mahmoudi Maribel Parra Shweta Hakre Leonard Chavez Kotaro Shirakawa Vincenzo Calvanese Brigitte Autran Francoise Barre-Sinoussi Monsef Benkirane Nicolas Chomont Tae-Wook Chun Sharon Lewin Christine Rouzious Didier Trono

Title Box Science 2010;329:174

Title Box